These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 21690478)

  • 1. Human epidermal growth factor eyedrops for cetuximab-related filamentary keratitis.
    Kawakami H; Sugioka K; Yonesaka K; Satoh T; Shimomura Y; Nakagawa K
    J Clin Oncol; 2011 Aug; 29(23):e678-9. PubMed ID: 21690478
    [No Abstract]   [Full Text] [Related]  

  • 2. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
    Cunningham D; Humblet Y; Siena S; Khayat D; Bleiberg H; Santoro A; Bets D; Mueser M; Harstrick A; Verslype C; Chau I; Van Cutsem E
    N Engl J Med; 2004 Jul; 351(4):337-45. PubMed ID: 15269313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case of ecthyma during therapy with an epidermal growth factor receptor inhibitor.
    Mizuno T; Tanegashima T; Suzuki A; Kuze S; Koyama T
    Eur J Dermatol; 2014; 24(4):511-2. PubMed ID: 25266748
    [No Abstract]   [Full Text] [Related]  

  • 4. Perifollicular xanthomas associated with epidermal growth factor receptor inhibitor therapy.
    Eames T; Kroth J; Flaig MJ; Ruzicka T; Wollenberg A
    Acta Derm Venereol; 2010 Mar; 90(2):202-3. PubMed ID: 20169314
    [No Abstract]   [Full Text] [Related]  

  • 5. New treatment options for colorectal cancer.
    Erlichman C; Sargent DJ
    N Engl J Med; 2004 Jul; 351(4):391-2. PubMed ID: 15269321
    [No Abstract]   [Full Text] [Related]  

  • 6. Can the addition of cetuximab to irinotecan improve outcome in colorectal cancer?
    Rosati G
    Nat Clin Pract Gastroenterol Hepatol; 2005 Jan; 2(1):20-1. PubMed ID: 16265095
    [No Abstract]   [Full Text] [Related]  

  • 7. Anti-EGFR monoclonal antibodies in metastatic colorectal cancer: time for an individualized approach?
    Fakih M
    Expert Rev Anticancer Ther; 2008 Sep; 8(9):1471-80. PubMed ID: 18759698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer.
    Bouchahda M; Macarulla T; Spano JP; Bachet JB; Lledo G; Andre T; Landi B; Tabernero J; Karaboué A; Domont J; Levi F; Rougier P
    Crit Rev Oncol Hematol; 2008 Sep; 67(3):255-62. PubMed ID: 18400508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor expression discrepancies in metastatic colorectal cancer patients treated with cetuximab plus irinotecan-based chemotherapy refractory to irinotecan and oxaliplatin.
    Han HS; Chang HJ; Hong YS; Kim SY; Lee KS; Jung KH
    Dis Colon Rectum; 2009 Jun; 52(6):1144-51; discussion 1152-3. PubMed ID: 19581859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cetuximab in metastatic colorectal cancer.
    Broadbridge VT; Karapetis CS; Price TJ
    Expert Rev Anticancer Ther; 2012 May; 12(5):555-65. PubMed ID: 22594891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer.
    Hebbar M; Wacrenier A; Desauw C; Romano O; Cattan S; Triboulet JP; Pruvot FR
    Anticancer Drugs; 2006 Aug; 17(7):855-7. PubMed ID: 16926635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case report and discussion of cetuximab-induced folliculitis.
    Adams DH; Nutt T
    Am J Clin Dermatol; 2006; 7(5):333-6. PubMed ID: 17007545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.
    Chung KY; Shia J; Kemeny NE; Shah M; Schwartz GK; Tse A; Hamilton A; Pan D; Schrag D; Schwartz L; Klimstra DS; Fridman D; Kelsen DP; Saltz LB
    J Clin Oncol; 2005 Mar; 23(9):1803-10. PubMed ID: 15677699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective analysis of KRAS wild-type patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 treatment regimens.
    Huang MY; Chen MJ; Tsai HL; Kuo CH; Ma CJ; Hou MF; Chuang SC; Lin SR; Wang JY
    Genet Mol Res; 2011 Oct; 10(4):3002-12. PubMed ID: 21968808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The efficacy of cetuximab for metastatic colorectal cancer].
    Katsumoto Y; Aritake N; Endoh A
    Gan To Kagaku Ryoho; 2010 Nov; 37(12):2523-5. PubMed ID: 21224627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persisting corneal erosion under cetuximab (Erbitux) treatment (epidermal growth factor receptor antibody).
    Foerster CG; Cursiefen C; Kruse FE
    Cornea; 2008 Jun; 27(5):612-4. PubMed ID: 18520515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical use of monoclonal antibodies to the epidermal growth factor receptor in colorectal cancer.
    Burtness B
    Oncology (Williston Park); 2007 Jul; 21(8):964-70; discussion 970, 974, 976-7. PubMed ID: 17715697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
    Vokes EE; Chu E
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
    Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
    Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy of cetuximab combined with chemotherapy for patients with advanced colorectal cancer and unclear K-ras status].
    Guo GF; Xia LP; Qiu HJ; Xu RH; Zhang B; Jiang WQ; Zhou FF; Wang F
    Zhonghua Zhong Liu Za Zhi; 2010 Oct; 32(10):777-81. PubMed ID: 21163071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.